Physician profile
Michael Scott Teuton
NPI 1861875312
$2,933.90
in general payments reported to CMS, 2019-2025
26 companies · $782 in 2025
The $782 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $180 · 2022: $461 · 2023: $785 · 2024: $726 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $715.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $330.78 | 2022-2025 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $273.94 | 2022-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $216.92 | 2023-2024 | |
| Pfizer INC. | $212.57 | 2022-2025 | |
| Medtronic, INC. | $208.65 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Lilly USA, LLC | $165.92 | 2021-2024 | Jardiance, Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $131.90 | 2023-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $103.67 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $97.28 | 2022-2023 | Spravato |
| Astellas Pharma US INC | $59.61 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.48 | 2024-2025 | Jardiance |
| Inspire Medical Systems, INC. | $51.44 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.69 | 2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $35.95 | 2023-2025 | Gvoke Hypopen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.73 | 2023-2025 | |
| Shield Therapeutics INC | $29.17 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.67 | 2022 | |
| Verona Pharma, INC. | $24.50 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $20.22 | 2023 | Rexulti |
| Amgen INC. | $19.06 | 2024 | Prolia, Evenity |
| Antares Pharma, INC. | $16.93 | 2024 | Xyosted |
| Nevro Corp. | $16.24 | 2022 | |
| Bioventus LLC | $16.11 | 2022 | |
| Neurocrine Biosciences, INC. | $16.00 | 2025 | |
| Tactile Systems Technology INC | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Teuton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.